Mutations in the epidermal growth factor receptor (EGFR) gene are commonly observed in
non-small-cell lung cancer (NSCLC), particularly in tumors of adenocarcinoma (ADC) …

KRAS is a frequent oncogenic driver in solid tumors, including non-small cell lung cancer
(NSCLC). It was previously thought to be an" undruggable" target due to the lack of deep …

Context.—In 2013, an evidence-based guideline was published by the College of American
Pathologists, the International Association for the Study of Lung Cancer, and the Association …

Objective To establish evidence-based recommendations for the molecular analysis of lung
cancers that are that are required to guide EGFR-and ALK-directed therapies, addressing …

Ethnic and geographic differences in cancer incidence, prognosis, and treatment outcomes
can be attributed to diversity in the inherited (germline) and somatic genome. Although …

Lung cancer is the leading cause of cancer mortality in the United States and worldwide.
Previously, lung cancer was simplistically divided into non–small-cell lung cancer (NSCLC) …

Cancer genomes from patients with African (AFR) ancestry have been poorly studied in
clinical research. We leverage two large genomic cohorts to investigate the relationship …

Introduction Previously, we reported the frequency of epidermal growth factor receptor
(EGFR) and KRAS mutations in nonsmall-cell lung cancer (NSCLC) patients in Latin …

One-hundred-fifty-three biliary cancers, including 70 intrahepatic cholangiocarcinomas
(ICC), 57 extrahepatic cholangiocarcinomas (ECC) and 26 gallbladder carcinomas (GBC) …

The majority of lung adenocarcinoma patients with epidermal growth factor receptor-(EGFR)
mutated or EML4–ALK rearrangement-positive tumors are sensitive to tyrosine kinase …